

Supporting Information

Phenalenyl Based Platinum Anticancer Compounds with Superior Efficacy: Design, Synthesis, Characterization, and Interaction with Nuclear DNA

Pradip Dutta^[a], Smita Kumari^[a], Justin Paulraj^[a], Rupali Sharma^[a], Gonela Vijaykumar^[b], Hari Sankar Das^[b], Sreejyothi P. ^[b], Swagata Sil^[b], Swadhin K. Mandal^[b], Aniruddha Sengupta^{[a]*}, Arindam Sarkar^{[a]*}


[a] India Innovation Research center

465 Patparganj Industrial Area, Delhi 110092.


Email: sararindam@gmail.com, asengupta@indiainnovationcenter.org

[b] Department of Chemical Sciences, Indian Institute of Science Education and Research-Kolkata, Mohanpur -741252, India.


Figures/Tables	Page No.
Figure S1. a), b), c) ^1H and d), e), f) ^{195}Pt NMR spectra of compounds 1 , 2 and 3 , respectively	3-4
Figure S2. Mass spectrum of compound 1 .	5
Figure S3. ^{13}C NMR spectrum of compound 1 .	5
Figure S4. Mass spec of compound 2 .	6
Figure S5. ^{13}C NMR spectrum of compound 2 .	6
Figure S6. Mass spectrum of compound 3b .	7
Figure S7. ^1H NMR spectrum of compound 3b .	7
Figure S8. ^{13}C NMR spectrum of compound 3b .	8
Figure S9. Mass spectrum of compound 3c .	8
Figure S10. ^1H NMR spectrum of compound 3c .	9
Figure S11. ^{13}C NMR spectrum of compound 3c .	9
Figure S12. Mass spectrum of compound 3c .	10
Figure S13. ^1H NMR spectrum of compound 3c .	10
Figure S14. Mass spectrum of compound 3 .	11
Figure S15. ^{13}C NMR spectrum of compound 3 .	11
Figure S16. HPLC profile of compound 3 .	12
Figure S17. Emission spectra of a) compound 1 , b) compound 2 and c) compound 3 in their respective γ_{max} of excitation wavelengths 420 nm (for 1), 600 nm (for 2) and 440 nm (for 3).	12
Figure S18. Morphology of A549 cells following treatment with compounds for 24 hours. (A) untreated, (B) compound 1 , (C) compound 2 , (D) compound 3 . Scale bar 20 μm .	12
Figure S19. Fluorescence intensity in A549 cells post treatment with compounds. (A) compound 1 ; (B) compound 2 ; (C) compound 3 . Scale bar 20 μm .	13
Figure S20. Representative images showing morphological changes of A549 nuclei. (A) untreated cells, showing normal nuclei; (B) cells treated with compound 1 show ring or necklace nuclear condensation (arrowhead). Scale bar 10 μm .	13
Figure S21. ^1H NMR monitoring of compound 1 in presence of PBS	14
Figure S22. ^1H NMR monitoring of compound 1 in presence of 5'-GMP	15
Figure S23. Mass spectrum of the reaction mixture of compound 1 and 5'-GMP	15
Table S1. Crystal data and structure refinement for complex 1 .	16



d)



e)



f)




Figure S1. a), b), c) ¹H and d), e), f) ¹⁹⁵Pt NMR spectra of compounds **1**, **2** and **3**, respectively.




Figure S2. Mass spectrum of compound 1.




Figure S3. ^{13}C NMR spectrum of compound 1.




Figure S4. Mass spectrum of compound 2.




Figure S5. ^{13}C NMR spectrum of compound 2.




Figure S6. Mass spectrum of compound 3b.




Figure S7. ¹H NMR spectrum of compound 3b.




Figure S8. ^{13}C NMR spectrum of compound **3b**.




Figure S9. Mass spectrum of compound **3c**.




Figure S10. ^1H NMR spectrum of compound **3c**.




Figure S11. ^{13}C NMR spectrum of compound **3c**.




Figure S12. Mass spectrum of compound **3c**.




Figure S13. ^1H NMR spectrum of compound **3c**.




Figure S14. Mass spectrum of compound 3.




Figure S15. ^{13}C NMR spectrum of compound 3.




Figure S16. HPLC profile of compound 3.




Figure S17. Emission spectra of a) compound 1, b) compound 2 and c) compound 3 in their respective γ_{max} of excitation wavelengths 420 nm (for 1), 600 nm (for 2) and 440 nm (for 3).




Figure S18. Morphology of A549 cells following treatment with compounds for 24 hours. (A) untreated, (B) compound 1, (C) compound 2, (D) compound 3. Scale bar 20 μm .




Figure S19. Fluorescence intensity in A549 cells post treatment with compounds. (A) compound 1; (B) compound 2; (C) compound 3. Scale bar 20 μm .




Figure S20. Representative images showing morphological changes of A549 nuclei. (A) untreated cells, showing normal nuclei; (B) cells treated with compound 1 show ring or necklace nuclear condensation (arrowhead). Scale bar 10 μm .




Figure S21. ¹H NMR monitoring of compound **1** in presence of PBS.




Figure S22. ¹H NMR monitoring of compound **1** in presence of 5'-GMP. (Black arrow indicates the change in H8 of 5'-GMP and Red arrows indicate the appearance of new peak after 2 h of 5'-GMP addition).




Figure S23. Mass spectrum of the reaction mixture of compound **1** and 5'-GMP

Table S1. Crystal data and structure refinement for complex **1**.

Empirical formula	C ₃₁ H ₂₇ Cl ₅ O ₆ Pt ₂ S ₂
Formula weight	1127.08
Temperature/K	293(2)
Crystal system	orthorhombic
Space group	P2 ₁ 2 ₁ 2 ₁
a/Å	13.4285(7)
b/Å	15.7599(9)
c/Å	16.4621(9)
α/°	90.00
β/°	90.00
γ/°	90.00
Volume/Å ³	3483.9(3)
Z	4
ρ _{calc} g/cm ³	2.149
μ/mm ⁻¹	8.568
F(000)	2136.0
Crystal size/mm ³	0.6 × 0.4 × 0.2
Radiation	MoKα ($\lambda = 0.71073$)
2Θ range for data collection/°	4.7 to 52.74
Index ranges	-15 ≤ h ≤ 16, -19 ≤ k ≤ 19, -20 ≤ l ≤ 19
Reflections collected	22167
Independent reflections	7112 [R _{int} = 0.0536, R _{sigma} = 0.0612]
Data/restraints/parameters	7112/0/419
Goodness-of-fit on F ²	1.069
Final R indexes [I>=2σ (I)]	R ₁ = 0.0408, wR ₂ = 0.0799
Final R indexes [all data]	R ₁ = 0.0690, wR ₂ = 0.0897
Largest diff. peak/hole / e Å ⁻³	0.64/-1.40
Flack parameter	-0.007(5)